Roth sitting on $4.50, page-24

Could not agree more with you morgenlofting, Many advantages of licensing rather than sale.

Absolutely for greater good to all for patients - and as you point out, using it in combo with several Pharma's would obviously mean more sales and returns for shareholders.

Also however, if VLA gets sold outright it would be on the basis of confirmed results. Thus there would be very little received for potential uses w.r.t other cancers. If there is a license of course, that would not matter. If VLA is later found to be useful with other cancer types, royalties will still flow thru to the company.

Of course there is also more risk, but if we are really confident results will continue, that is somewhat reduced.

Have a great day.

KMS